Pharmacoeconomic Study Assessing the Cost of Chronic Hepatitis C Treatment With Peginterferon Alfa-2b (PegIntron) and Ribavirin (Rebetol) in the Czech Republic (Study P04588)(COMPLETED)

Merck Sharp & Dohme (MSD)

Status: Completed

Conditions: Hepatitis C, Chronic; Hepatitis C

Treatments: Biological: peginterferon alfa-2b; Drug: ribavirin

Study type: Observational

Funder types: Industry

Identifiers

NCT00723632

P04588

Details and patient eligibility

About

The objective of the study is to evaluate the costs associated with peginterferon alfa-2b (PegIntron) plus ribavirin (Rebetol) treatment for chronic hepatitis C in the Czech Republic. Only costs associated with rescue medication, concomitant therapy, disease monitoring, and medical intervention costs recognized by the treating institution as treatment-related expenses will be included in the analysis. The study will also evaluate the correlation between hepatitis C virus (HCV) therapy-related costs with ribavirin dosing and participant history.

Enrollment: 901 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participants with chronic hepatitis C
• At least 18 years old
• Eligibility determined based on the diagnosis and medical judgment only.

Exclusion criteria

• None

Trial design

901 participants in 1 patient group

Peginterferon alfa-2b and ribavirin

Description:

All participants included in the study

Treatment:

Drug: ribavirin

Biological: peginterferon alfa-2b